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88S Abstracts May Supplement 2013CI, 1.3-3.9; P < .01), and any type II endoleak (OR, 1.7;
95% CI, 1.1-2.6; P < .01). SacDe was more likely to occur
in smokers (OR, 1.7; 95% CI, 1.2-2.4; P < .01), and less
likely to occur in patients who had iliac aneurysm repair
(OR, 0.7; 95% CI, 0.5-0.95; P ¼ .02), and any re-interven-
tion (OR, 0.6; 95% CI, 0.4-0.9; P ¼ .03). Risk adjusted
(age, symptoms/rupture, reintervention, hypogastric
coverage, low EF, smoking) Cox regression showed that
SacIn independently predicted increase in late mortality
(HR, 2.2; 95% CI, 1.4-3.7; P < .01), while SacDe had
no impact (HR, 0.9; 95% CI, 0.6-1.3; P ¼ .5). Long-
term survival was lower (log-rank, P < .01) in patients
with SacIn (94 6 2% 1 yr and 57 6 6% 5 yr) compared
to all others (99 6 1% 1 yr and 81 6 2% 5 yr).
Conclusions: These data suggest that AAA sac size
increase greater than 5 mm at one year, albeit infrequent
is an independent predictor of late mortality and warrants
close observation and early intervention.
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Objectives: Total arch repair (TAR) is the gold stan-
dard therapy for arch aneurysm, however, there is room
for improvements. We present the outcome of our endo-
vascular strategy for arch aneurysms.
Methods: During the last 3 years, we performed
Chimney technique (38 cases) and the Retrograde In-situ
Branched Stent grafting (RIBS, seven cases) to treat 45
patients with arch aneurysms all of whom were considered
to be at high risk for TAR. The chimney technique involves
a uni or bi-lateral common carotid artery exposure and inser-
tionof a small diameter covered stent to preserve cerebralﬂow
in conjunction with the deployment of the main endograft in
the ascending aorta. The RIBS method was developed in an
aim to reduce gutter endoleak associated with the Chimney
technique. The RIBS procedure is performed by puncturing
the main endograft in a retrograde manner and followed by
balloon dilatation and covered stent deployment.
Results: The mean aneurysm diameter (short axis) was
6.6 cm. The overall OR time was 318 6 126 minutes and
blood loss was 703 6 730 mL and 12 (26%) patients
required blood transfusion. Endoleak was encountered in
three (7.9%) cases and all were among the Chimney
patients as a result of gutter EL. There were no cases
with endoleak among the RIBS patients. There was one
mortality (2.2 %) that resulted from intraoperative retro-
grade type A dissection. Stroke occurred in one case
(2.2%) but it was minor and resolved completely.
Combined stroke death rate was 4.4%. During a mean
FU of 11.266.9 months, no aneurysm rupture has been
encountered.Conclusions: Both the Chimney technique and the
RIBS procedure are safe and effective and can be consid-
ered as an alternative option for those patients unﬁt for
TAR. RIBS appear to be advantageous in further elimi-
nating gutter endoleak.
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Objectives: During EVAR for ruptured AAA (r-AAA)
inadequate aortic neck morphology often requires
surgeons to expand the stent graft ‘indications for use’
(IFU). This is the ﬁrst study to date that evaluates
outcomes of patients with r-AAA that underwent EVAR
with favorable aortic neck (f-AN) vs hostile aortic neck
(h-AN), vs open surgical repair (OSR).
Methods: Over a 5-year period, 180 patients with
r-AAA underwent EVAR (n ¼ 74; 41.1%) or OSR (n ¼
106; 58.9%). The 74 r-EVAR patients were divided into
2 groups based on f-AN (n ¼ 25; 33.7%) vs h-AN (n ¼
49; 66.7%) morphology. Data was collected prospectively,
and aortic neck measurements were standardized relative to
the IFUs of particular stent graft. Patients were analyzed on
an intention-to-treat basis and outcomes were evaluated by
logistic regression multivariable analysis.
Results: The 30-daymortalitywas the lowest in r-EVAR
patientswith f-ANand the highest in theOSRpatients (f-AN,
8%; h-AN, 23%;OSR, 43.4%; P< .01), and both f-AN and h-
AN r-EVAR patients had a better cumulative 3-year survival
than OSR (f-AN, 64%; h-AN, 67%; OSR, 44%; P < .01).
The r-EVAR patients with h-AN had a signiﬁcantly higher
incidence of female gender (32% vs 19%; P < .05), mean
maximum AAA diameter (7.4 cm vs 5.5 cm; P < .05),
abdominal compartment syndrome (ACS) (20% vs 4%; P <
.05), Type I endoleaks (16% vs 4%; P < .05), and the need
for all secondary interventions (77% vs 40%; P < .05).
Conclusions: For r-AAA, although EVAR provides the
greatest beneﬁt to patients with f-AN, even patients with
h-AN experience a survival beneﬁt at 3 years when com-
pared to OSR. However, r-EVAR patients with h-AN expe-
rience a higher incidence of ACS, Type I endoleaks, and
secondary interventions, and mandate vigilant follow-up.
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